Australia's Therapeutics Goods Administration provisionally approved Pfizer Inc PFE / BioNTech SE's BNTX COVID-19 vaccine for children between 5 and 11 years. The health minister said that the rollout could begin from January 10, 2022.
- The FDA approved Pfizer/BioNTech COVID-19 vaccine for emergency use in kids aged 5-11 years in October.
- "The authority has made a careful, thorough assessment, determined that it is safe and effective and that it is in the interests of children and Australians for children 5 to 11 to be vaccinated," said Health Minister Greg Hunt.
- The efficacy of vaccines against the new Omicron variant, which is spreading in Australia, remains unknown.
- Parliament House was closed over the weekend to the public until further notice after a staffer to a member of parliament tested positive to COVID-19 after the legislature's final sitting week of the year on Friday.
- Also Read: Pfizer-BioNTech's COVID-19 Vaccine Shows 100% Effectiveness In Long Term Analysis In Adolescents.
- The European Union also backed the vaccine for use in children between 5 and 11 years.
- Price Action: PFE stock traded 0.11% higher at $54.33, and BNTX shares are trading 4.09% lower at $330 on the last check Monday.
- Photo by x3 from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in